This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gevers, E. F. Articles by Robinson, I. C. A. F. Search for Related Content PubMed PubMed Citation Articles by Gevers, E. F. Articles by Robinson, I. C. A. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB PARATHYROID HORMONE

Bone Marrow Adipocytes: A Neglected Target Tissue for Growth Hormone

Division of Molecular Neuroendocrinology (E.F.G., I.C.A.F.R.), National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom; and Bone Research Group (Medical Research Council) (N.L.), University of Cambridge, Department of Medicine, Addenbrooke’s Hospital, Cambridge CB2 2QQ, United Kingdom

Address all correspondence and requests for reprints to: Dr. Evelien F. Gevers, Division of Molecular Neuroendocrinology, National Institute for Medical Research, The Ridgeway, Mill Hill, London NW7 1AA, United Kingdom. E-mail: egevers{at}nimr.mrc.ac.uk.

Bone marrow (BM) contains numerous adipocytes. These share a common precursor with osteoblasts and chondrocytes, but their function is unknown. It is unclear what regulates the differentiation of these three different cell types, though their subsequent metabolic activity is under hormonal regulation. GH and estrogen stimulate bone growth and mineralization, by direct effects on chondrocytes and osteoblasts. GH also stimulates lipolysis in subcutaneous and visceral adipocytes. However, adipocytes in BM have largely been ignored as potential targets for GH or estrogen action. We have addressed this by measuring BM adipocyte number, perimeter and area as well as bone area and osteoblast activity in GH-deficient dwarf (dw/dw), normal, or ovariectomized (Ovx) rats, with or without GH, IGF-1, PTH, or estrogen treatment or high fat feeding.

Marrow adipocyte numbers were increased 5-fold (P < 0.001) in dw/dw rats, and cell size was also increased by 20%. These values returned toward normal in dw/dw rats given GH but not when given IGF-1. Cancellous bone area and osteoblast number were significantly (P < 0.005) lower in dw/dw rats, though alkaline phosphatase (ALP) activity in individual osteoblasts was unchanged. GH treatment increased % osteoblast covered bone surface without affecting individual cell ALP activity. Ovariectomy in normal or dw/dw rats had no affect on marrow adipocyte number nor size, although estrogen treatment in ovariectomized (Ovx) normal rats did increase adipocyte number. Ovx decreased tibial cancellous bone area in normal rats (64%; P < 0.05) and decreased osteoblast ALP-activity (P < 0.01) but did not affect the percentage of osteoblast-covered bone surface. Estrogen replacement reversed these changes. While treatment with PTH by continuous sc infusion decreased cancellous bone (P < 0.05) and high fat feeding increased the size of BM adipocytes (P < 0.01), they did not affect BM adipocyte number. These results suggest that GH has a specific action on BM adipocytes that is not simply due to altered bone or fat metabolism.

We conclude that the marrow adipocyte lineage is an important and specific target for GH action. The inverse relationship between adipocyte number and osteoblast covered bone surface, together with the well-known effects of GH on epiphysial chondrocytes leads us to propose that GH plays two important roles on cells of all three lineages. During differentiation, it regulates the numbers of each cell type that are maintained from the common precursor lineage. Subsequently it has cell-specific effects on the metabolic activities of the differentiated cells. In the case of marrow adipocytes, GH-dependent lipolysis could provide an important hormonally regulated local high energy source in bone.

This article has been cited by other articles:

				A. Giustina, G. Mazziotti, and E. Canalis Growth Hormone, Insulin-Like Growth Factors, and the Skeleton Endocr. Rev., August 1, 2008; 29(5): 535 - 559. [Abstract] [Full Text] [PDF]

				F. C. Mansergh, T. Wells, C. Elford, S. L. Evans, M. J. Perry, M. J. Evans, and B. A. J. Evans Osteopenia in Sparc (osteonectin)-deficient mice: characterization of phenotypic determinants of femoral strength and changes in gene expression Physiol Genomics, December 19, 2007; 32(1): 64 - 73. [Abstract] [Full Text] [PDF]

				J. S. Davies, E. F. Gevers, A. E. Stevenson, K. T. Coschigano, M. M. El-Kasti, M. J. Bull, C. Elford, B. A. J. Evans, J. J. Kopchick, and T. Wells Adiposity profile in the dwarf rat: an unusually lean model of profound growth hormone deficiency Am J Physiol Endocrinol Metab, May 1, 2007; 292(5): E1483 - E1494. [Abstract] [Full Text] [PDF]

				M.A. Garcia-Perez, I. Noguera, C. Hermenegildo, A. Martinez-Romero, J.J. Tarin, and A. Cano Alterations in the phenotype and function of immune cells in ovariectomy-induced osteopenic mice Hum. Reprod., April 1, 2006; 21(4): 880 - 887. [Abstract] [Full Text] [PDF]

				Y. Appiagyei-Dankah, C. D. Tapiador, J. F. Evans, M. Castro-Magana, J. F. Aloia, and J. K. Yeh Influence of growth hormone on bone marrow adipogenesis in hypophysectomized rats Am J Physiol Endocrinol Metab, March 1, 2003; 284(3): E566 - E573. [Abstract] [Full Text] [PDF]